FDA approves ViiV's dolutegravir

FDA approved an NDA from ViiV Healthcare Ltd. for Tivicay dolutegravir to treat HIV infection in treatment-naïve and treatment-experienced patients ages 12 and over. The drug had Priority Review and is the first from ViiV's pipeline to be approved. The HIV integrase inhibitor is also under review in the EU and Canada. ViiV is a JV between GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Pfizer Inc. (NYSE:PFE). ...